Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, have been published in Clinical Genitourinary Cancer.
The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
Discover more about how we help to shape the future of oncology treatments here.
Jump to a slide with the slide dots.
Inizio accelerates growth with a trio of strategic leadership appointments
Inizio has appointed Colin Stanley as CCO, Remco op den Kelder as President of Inizio Advisory and Jim Sage as President of Inizio Engage
Read moreStefanie Christmas, Global Head of Diversity, Equity, & Inclusion, named 2025 Presidential Leadership Scholar
Stefanie Christmas has been named one of 57 Scholars who will form the Presidential Leadership Scholars’ (PLS) 10th annual class.
Read moreInizio booth earns silver for Best Sustainability Experience
We are delighted to have been awarded Silver for Best Sustainability Experience at Event Marketer’s 2024 Experience Design Awards.
Read more